ArticleFrontiers in immunology2026
Case Report: From idiopathic recurrent pericarditis to systemic Behçet's Disease: unmasking a unified IL-1-driven autoinflammatory phenotype.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recurrent idiopathic recurrent pericarditis (RP) is increasingly recognized as an organ-specific autoinflammatory syndrome driven by the interleukin-1 (IL-1) axis. Behçet's Disease (BD), a systemic vasculitis, exhibits significant pathogenetic overlap with RP through IL-1 mediated hyperinflammation, particularly in phenotypes dominated by serositis. The clinical evolution of prolonged, seemingly idiopathic RP into overt, systemic BD upon the tapering of targeted therapy remains a critical, yet underreported, observation. Case presentation: A 42 years old female with corticosteroid-dependent, colchicine-resistant RP achieved complete and sustained clinical and biochemical remission using the IL-1 receptor antagonist, Anakinra, for almost 30 months, despite the tapering started after 18 months of continuous therapy with Anakinra, associated to colchicine and a quick tapering and withdrawal of corticosteroids. Following the elective tapering of Anakinra, the patient remained stable for three months with a dose of an injection of 100mg of Anakinra three times per week, before suffering a severe pericardial relapse concurrent with the systemic onset of systemic BD. The clinical condition observed fulfilled the International Criteria for Behçet's Disease (ICBD), featuring recurrent oral and genital ulcerations, erythema nodosum and a positive pathergy test. The immediate reinitiation of Anakinra (100mg daily) led to the rapid and complete resolution of both the pericardial inflammation and all systemic mucocutaneous manifestations. Conclusions: This case highlights a potential pathogenetic overlap between refractory RP and serositis-dominant BD phenotypes, suggesting that isolated RP may, in select cases, represent an early mono-organ precursor of a systemic autoinflammatory propensity. Furthermore, it provides clinical rationale for considering IL-1 blockade in serositis-dominant BD, though larger prospective studies are needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.